ATE278962T1 - C-MYC-BINDENDES PROTEIN ßC-MYC CODING REGION DETERMINANT-BINDING PROTEIN (CRD-BP)ß - Google Patents

C-MYC-BINDENDES PROTEIN ßC-MYC CODING REGION DETERMINANT-BINDING PROTEIN (CRD-BP)ß

Info

Publication number
ATE278962T1
ATE278962T1 AT99912296T AT99912296T ATE278962T1 AT E278962 T1 ATE278962 T1 AT E278962T1 AT 99912296 T AT99912296 T AT 99912296T AT 99912296 T AT99912296 T AT 99912296T AT E278962 T1 ATE278962 T1 AT E278962T1
Authority
AT
Austria
Prior art keywords
binding protein
myc
crd
coding region
region determinant
Prior art date
Application number
AT99912296T
Other languages
English (en)
Inventor
Jeffrey Ross
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Application granted granted Critical
Publication of ATE278962T1 publication Critical patent/ATE278962T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99912296T 1998-03-09 1999-03-05 C-MYC-BINDENDES PROTEIN ßC-MYC CODING REGION DETERMINANT-BINDING PROTEIN (CRD-BP)ß ATE278962T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7737298P 1998-03-09 1998-03-09
PCT/US1999/004897 WO1999046594A2 (en) 1998-03-09 1999-03-05 C-myc coding region determinant-binding protein (crd-bp)

Publications (1)

Publication Number Publication Date
ATE278962T1 true ATE278962T1 (de) 2004-10-15

Family

ID=22137674

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912296T ATE278962T1 (de) 1998-03-09 1999-03-05 C-MYC-BINDENDES PROTEIN ßC-MYC CODING REGION DETERMINANT-BINDING PROTEIN (CRD-BP)ß

Country Status (10)

Country Link
US (2) US6255055B1 (de)
EP (1) EP1062514B1 (de)
JP (1) JP3535095B2 (de)
AT (1) ATE278962T1 (de)
AU (1) AU733428B2 (de)
CA (1) CA2321610C (de)
DE (1) DE69920885T2 (de)
IL (1) IL138060A (de)
NZ (1) NZ506480A (de)
WO (1) WO1999046594A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696247B2 (en) 1998-03-18 2004-02-24 Corixa Corporation Compounds and methods for therapy and diagnosis of lung cancer
US6960570B2 (en) 1998-03-18 2005-11-01 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US7579160B2 (en) * 1998-03-18 2009-08-25 Corixa Corporation Methods for the detection of cervical cancer
US7258860B2 (en) 1998-03-18 2007-08-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
US6297364B1 (en) * 1998-04-17 2001-10-02 Ludwig Institute For Cancer Research Isolated nucleic acid molecule encoding cancer associated antigen, the antigen itself, and uses thereof
US7314926B1 (en) * 1999-04-08 2008-01-01 Antisoma Research Limited Antiproliferative activity of g-rich oligonucleotides and method of using same to bind to nucleolin
US8114850B2 (en) * 1999-04-08 2012-02-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318889A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US20080318890A1 (en) * 1999-04-08 2008-12-25 Antisoma Research Limited Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
US7960540B2 (en) * 1999-04-08 2011-06-14 Advanced Cancer Therapeutics, Llc Antiproliferative activity of G-rich oligonucleotides and method of using same to bind to nucleolin
WO2002020036A1 (de) * 2000-09-06 2002-03-14 Mueller Friederike Arzneimittel mit einer für das rna-bindende koc-protein kodierenden dna-sequenz, einem koc-protein oder einer dna-sequenz des koc-promotors
DE102004026135A1 (de) * 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide
US7632828B2 (en) * 2004-06-10 2009-12-15 Fob Synthesis, Inc. Gram-positive carbapenem antibacterials and processes for their preparation
WO2006038212A2 (en) * 2004-10-04 2006-04-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods and compositions for the diagnosis and treatment of cancer
PL2325306T3 (pl) 2005-02-25 2014-07-31 Oncotherapy Science Inc Szczepionki peptydowe do zastosowania w nowotworach płuc, wykazujących ekspresję polipeptydów TTK, URLC10 lub KOC1
WO2008020652A1 (en) * 2006-08-18 2008-02-21 Oncotherapy Science, Inc. Imp-1 oncogene as a therapeutic target and prognostic indicator for lung cancer
US20090131351A1 (en) * 2007-11-16 2009-05-21 Antisoma Research Limited Methods, compositions, and kits for modulating tumor cell proliferation
RS53872B2 (sr) 2008-05-14 2018-06-29 Immatics Biotechnologies Gmbh Novi i snažni mhc peptidi klase ii izvedeni iz survivina i neurokana
EP4353321A3 (de) * 2014-08-04 2024-07-10 OncoTherapy Science, Inc. Koc1-abgeleitetes peptid und impfstoff damit
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
FI3273986T3 (fi) 2015-03-27 2024-02-07 Immatics Biotechnologies Gmbh Uusia peptidejä ja peptidien yhdistelmiä käytettäväksi immunoterapiassa eri syöpiä vastaan

Also Published As

Publication number Publication date
WO1999046594A2 (en) 1999-09-16
US6255055B1 (en) 2001-07-03
AU3069799A (en) 1999-09-27
US20020061543A1 (en) 2002-05-23
US6794151B2 (en) 2004-09-21
NZ506480A (en) 2003-06-30
JP2002506971A (ja) 2002-03-05
EP1062514A2 (de) 2000-12-27
AU733428B2 (en) 2001-05-17
IL138060A0 (en) 2001-10-31
DE69920885D1 (en) 2004-11-11
DE69920885T2 (de) 2006-02-02
WO1999046594A3 (en) 1999-12-09
EP1062514B1 (de) 2004-10-06
CA2321610C (en) 2005-12-20
IL138060A (en) 2005-03-20
JP3535095B2 (ja) 2004-06-07
CA2321610A1 (en) 1999-09-16

Similar Documents

Publication Publication Date Title
IL138060A0 (en) C-myc coding region determinant-binding protein (crd-bp)
Vicini et al. Low-dose-rate brachytherapy as the sole radiation modality in the management of patients with early-stage breast cancer treated with breast-conserving therapy: preliminary results of a pilot trial
NO976063L (no) Fremgangsmåte for behandling av diabetes
AU2002366802A1 (en) Systems and methods for treating patients with collagen-rich material extracted from adipose tissue
ATE194660T1 (de) Veraendertes gen bei menschlichem colorektalem- krebs
NO990001L (no) Fremstilling og bruk av Radium-223 ved behandling av forkalket vev i forbindelse med smertelindring, ved benkreft og behandling av benoverflaten
DE69633195D1 (de) Injektierbare oder implantierbare biomaterialien zum füllen oder abdecken von hohlräumen und lumen eines körpers
PT927150E (pt) Compostos de lipoxina e sua utilizacao no tratamento de doencas proliferativas celulares
AU2003253986A1 (en) Gene expression profiling in biopsied tumor tissues
DE69814394D1 (de) Verwendung von levobupivacain
EP1593407A3 (de) Strahlungsschutzvorrichtung
WO2004101024A3 (en) Method for treating glandular diseases and malignancies
DE50014532D1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
DK1117783T3 (da) Gen udtrykt i prostatacancer
ATE374618T1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
DE60044350D1 (de) Prostata-spezifisches gen pcgem1 und methoden zu dessen verwendung zur erkennung, behandlung und prävention von prostatakrebs
DE60224299D1 (de) Kombinationsmedikationen mit einem selektiven cyclooxygenase-2-inhibitor
GR3006236T3 (de)
AU2003266228A1 (en) Diagnostic agent, method for detecting a carcinoma, and means for the treatment thereof
BG102177A (en) Surgical method for organconservation treatment of cancer of the mammary gland
SE9103546D0 (sv) Middle ear ventilation tube
FI113153B (fi) Solukasvunsäätelijä
游瑞欽 et al. The Lateral Supramalleolar Flap-Technical Refinements
MX9706725A (es) Mezclas enzimaticas definidas, novedosas para obtener celulas y para tratamientos de heridas.
EP1321146A3 (de) Typ 5 und Typ 3 17 Beta-Hydroxisteroid-Dehydrogenasehemmer und Verfahren zu ihrer Anwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties